RT Journal Article
T1 Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.
A1 Mendoza, Nicolas
A1 Diaz-Ropero, Maria Paz
A1 Aragon, Miguel
A1 Maldonado, Vicente
A1 Llaneza, Placido
A1 Lorente, Juan
A1 Mendoza-Tesarik, Raquel
A1 Maldonado-Lobon, Jose
A1 Olivares, Monica
A1 Fonolla, Juristo
K1 -chiro-inositol
K1 ICSI
K1 Myo-inositol
K1 polycystic ovary syndrome
K1 pregnancy rate
AB The purpose of this study was to evaluate the effect of two doses of D-chiro-inositol (DCI) in combination with Myo-inositol (MYO) in women with PCOS undergoing ICSI. This was a multicenter controlled, randomized, double-blind parallel group study with two MYO-DCI formulations for 12 weeks. The study group (SG) was administered 550 mg of MYO + 150 mg of DCI twice daily; the control group (CG) was administered 550 mg of MYO + 13.8 mg of DCI twice daily. The participants comprised 60 women with PCOS undergoing ICSI. At baseline, no differences were found between the two groups regarding age, BMI, HOMA-IR or testosterone levels. The pregnancy and live birth rates were significantly higher in the SG than in the CG (65.5 vs. 25.9 and 55.2 vs. 14.8, respectively) [risk ratio (RR) = 0.4; 95%CI (0.2, 0.79); p = .003 and RR = 0.27; 95%CI (0.10, 0.70); p = .002 respectively]. The risk of ovarian hyperstimulation syndrome (OHSS) was lower in the SG (3.44 vs. 18.5%, p = .07). The combination of MYO-DCI at high doses of DCI improves the pregnancy rates and reduces the risk of OHSS in women with PCOS undergoing ICSI.
YR 2019
FD 2019-03-16
LK http://hdl.handle.net/10668/13723
UL http://hdl.handle.net/10668/13723
LA en
DS RISalud
RD Apr 5, 2025